Canadian review of Upjohn’s Depo-Provera
On June 7, Upjohn will appeal Canadian Health Protection Branch's decision not to approve the application for Depo- Provera's use as a contraceptive until HPB's concerns about the drug's long-term safety are satisfied. In December, Canada issued a "notice of noncompliance" because it wants further information on the slight increase in risk of breast cancer in women under 35 that was seen in WHO's study of Depo-Provera. WHO said the risk was similar to that of oral contraceptives. HPB also wants more information on a decrease in bone density seen in a small study. To start the appeal, Upjohn will submit answers to these questions to the HPB. The Depo-Provera submission has been pending since 1983.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth